Investigation of Pharmacokinetics and Absolute Bioavailability of BI 1358894 Administered Orally as Tablet Co-administered With an Intravenous Microtracer Dose of [C-14]-BI 1358894 in Healthy Male Volunteers Via a Non-randomised, Open-label, Fixed-sequence Trial (Part 1) Followed by a Randomised, Open-label, Single-dose, Two-period, Two-sequence Cross-over Relative Bioavailability Trial in BI 1358894 Oral Suspension (Part 2)
Latest Information Update: 02 Apr 2025
At a glance
- Drugs BI 1358894 (Primary) ; BI 1358894 (Primary) ; BI 1358894 (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Oct 2020 Status changed from active, no longer recruiting to completed.
- 30 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2020 Planned End Date changed from 28 Oct 2020 to 30 Sep 2020.